Bristol-Myers Squibb to Divest Celgene’s Otezla (apremilast) to Gain the US FTC’s Approval on Celgene Acquisition

 Bristol-Myers Squibb to Divest Celgene’s Otezla (apremilast) to Gain the US FTC’s Approval on Celgene Acquisition

Bristol-Myers Squibb to Divest Celgene’s Otezla (apremilast) to Gain the US FTC’s Approval on Celgene Acquisition

Shots:

  • BMS plans to divest Otezla to address US Federal Trade Commission concern to close pending Celgene acquisition for $74B more quickly
  • In Jan’2019, BMS announced to acquire Celgene with its expected closing of the transaction in H2’19 or H1’20. The divestiture of Otezla will accelerate BMS post-closing deleveraging plans
  • Otezla is a PDE4 inhibitor, approved to treat moderate to severe plaque psoriasis and has generated a revenue of $1.6B in 2018

Click here to read full press release/ article | Ref: BMS | Image: SPJ News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post